# Sree Rayalaseema Hi-Strength Hypo share price today (Sree Rayalaseema Hi-Strength Hypo Ltd, NSE: SRHHYPOLTD)

> Sree Rayalaseema Hi-Strength Hypo share price today: ₹490.20 at the NSE close on 3 November 2026, down 11.2% in a year. Sree Rayalaseema Hi-Strength Hypo (NSE: SRHHYPOLTD) is worth ₹842 crore, trades at a P/E of 8.5 and has closed between ₹406.85 and ₹596.70 over the past 52 weeks. > Sree Rayalaseema Hi-Strength Hypo Ltd's earnings have grown faster than its share price. Earnings per share grew +1.5% in a year while the price moved −11.2%. SRHHYPOLTD · Chemicals - Inorganic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sree-rayalaseema-hi-strength-hypo-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹490.20 (−11.2% in a year)
- P/E: 8.5× (lower than 63% of the last 11 years)
- Revenue (Jun 2026): ₹211 Cr (+17.2% on a year ago)
- Profit (Jun 2026): ₹25.0 Cr (+13.6% on a year ago)
- Operating margin: 14.0% (−1.0 points on a year ago)
- ROCE: 14%, FY26
- ROIC: 11.1%, against a 12.0% cost of capital: −0.9 points

Biggest thing to watch: the price has already been rising for 5 weeks, so timing is the risk more than the business. ## What is the Sree Rayalaseema Hi-Strength Hypo share price today? Sree Rayalaseema Hi-Strength Hypo Ltd's share price was ₹490.20 at the close on 3 November 2026. It has been rising for 5 weeks. That is 4.3% below its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 11 weeks in a row. In the last 52 weeks it traded between ₹407 and ₹597, and at that close it sat 44% of the way up from that low. Over the last 11 years the share price moved +755% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sree Rayalaseema Hi-Strength Hypo this quarter? Two changes stood out: revenue up on a year earlier for 5 quarters in a row and highest quarterly revenue in 10 quarters. 1. Revenue up on a year earlier for 5 quarters in a row In the June 2026 quarter revenue was ₹211 crore, +17.2% on a year earlier. 2. Highest quarterly revenue in 10 quarters Revenue of ₹211 crore in the June 2026 quarter is the highest of the last 10 quarters. ## What are Sree Rayalaseema Hi-Strength Hypo's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Sree Rayalaseema Hi-Strength Hypo reported revenue of ₹211 crore, up 17.2% from ₹180 crore a year earlier, and a profit of ₹25.0 crore, up 13.6% from ₹22.0 crore. ### Sree Rayalaseema Hi-Strength Hypo results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹211 crore | ₹180 crore | +17.2% |
| Profit | ₹25.0 crore | ₹22.0 crore | +13.6% |
| Earnings per share | ₹14.28 | ₹12.77 | +11.8% |
| Operating margin | 14.0% | 15.0% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Sree Rayalaseema Hi-Strength Hypo share price history? Sree Rayalaseema Hi-Strength Hypo closed at ₹490.20 on 3 November 2026, down 11.2% from ₹552.20 a year earlier (31 October 2025) and up 41.2% over five years. Its highest weekly close since March 2016 was ₹896.20 on 11 October 2024. ### Sree Rayalaseema Hi-Strength Hypo share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹473.85 | +3.5% |
| 1 month ago · 1 Oct 2026 | ₹543.90 | −9.9% |
| 6 months ago · 30 Apr 2026 | ₹488.90 | +0.3% |
| 1 year ago · 31 Oct 2025 | ₹552.20 | −11.2% |
| 3 years ago · 3 Nov 2023 | ₹546.80 | −10.4% |
| 5 years ago · 4 Nov 2021 | ₹347.05 | +41.2% |
| 10 years ago · 4 Nov 2016 | ₹161.90 | +202.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹57.30 | +755.5% |
| Highest weekly close since March 2016 · 11 Oct 2024 | ₹896.20 | −45.3% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹56.00 | +775.4% |
| 52-week high (weekly close) · 25 Sep 2026 | ₹596.70 | −17.8% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹406.85 | +20.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (561 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Sree Rayalaseema Hi-Strength Hypo? 3 Nov 2026: Sree Rayalaseema Hi-Strength Hypo closed at ₹490.20, up 3.5% on the week and down 9.9% on the month. 18 Sep 2026: ex-date for a dividend of ₹3 a share. ### Earlier

- Results for April to June 2026: Revenue up 17.2% and profit up 13.6% on a year earlier. ## What dividend does Sree Rayalaseema Hi-Strength Hypo pay? Sree Rayalaseema Hi-Strength Hypo paid ₹3 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.61% at the ₹490.20 close on 3 November 2026. The last was a dividend of ₹3 a share, ex-date 18 September 2026. ### Sree Rayalaseema Hi-Strength Hypo dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 18 Sep 2026 | ₹3 | Dividend |
| 19 Sep 2025 | ₹3 | Dividend |
| 12 Sep 2024 | ₹3 | Dividend |
| 18 Sep 2023 | ₹4 | Dividend |
| 21 Sep 2022 | ₹3.50 | Dividend |
| 22 Sep 2021 | ₹3 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Sree Rayalaseema Hi-Strength Hypo Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in each of its last 9 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Sree Rayalaseema Hi-Strength Hypo on? Sree Rayalaseema Hi-Strength Hypo is not on any of our India lists this week. ## Is Sree Rayalaseema Hi-Strength Hypo profitable? Sree Rayalaseema Hi-Strength Hypo Ltd earned ₹25.0 Cr of net profit in the Jun 2026 quarter, +13.6% on the same quarter a year earlier. Full-year FY26 profit was ₹90.0 Cr. Over 10 years profit has grown 13.7% a year on average. That is 11.8% of the quarter's revenue. The same quarter a year earlier earned ₹22.0 Cr. For the full year, FY26 profit was ₹90.0 Cr (+3.4% on the year before). Why profit moved: revenue changed +17.2% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +1.4% and revenue +7.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Sree Rayalaseema Hi-Strength Hypo make, and is it growing? Sree Rayalaseema Hi-Strength Hypo Ltd reported ₹211 Cr of revenue in the Jun 2026 quarter, +17.2% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 6.3% a year on average. The last full year, FY26, came in at ₹667 Cr. The last four reported quarters add to ₹697 Cr. FY26 revenue was ₹667 Cr, +4.5% on the year before. Recent pace: the last four quarters grew +7.1% on average, against 6.3% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.6%, against −5.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +1.1%, against +11.5% a year (rolling over). ## How much of every ₹100 of sales does Sree Rayalaseema Hi-Strength Hypo keep? Sree Rayalaseema Hi-Strength Hypo Ltd's operating margin was 14.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 9 years it has been between 11.0% and 15.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.3 percentage points on the year while gross margin changed −4.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Sree Rayalaseema Hi-Strength Hypo's profit turning into cash? Over the last 3 years, 95% of Sree Rayalaseema Hi-Strength Hypo Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹39.0 Cr of operating cash against ₹90.0 Cr of profit. After ₹4.0 Cr of spending on assets, ₹35.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 95% of profit came in as cash: the cash cycle got 31 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.5× depreciation over three years. The next section checks what that spending is building. ## Where does Sree Rayalaseema Hi-Strength Hypo's cash go? Sree Rayalaseema Hi-Strength Hypo Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 88 days in FY26, up from 57 days in FY21. It spent ₹38.0 Cr on assets over the last 3 years. Customers take 46 days to pay, and stock sits for 55 days on average. At FY26 sales of ₹667 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹161 Cr is tied up in the business at any time. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 55 days. Customers pay about 46 days after that. Suppliers are paid at 13 days. Together that makes the 88-day cycle. Spending on assets: ₹38.0 Cr over the last 3 years, against ₹25.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sree Rayalaseema Hi-Strength Hypo's P/E ratio, and how does it compare with its own history? Sree Rayalaseema Hi-Strength Hypo Ltd's P/E is 8.5×, in the middle of its own history: higher than 37% of past readings. Its usual P/E (the middle reading) is 9.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹53.23. Why the multiple is where it is: over the past year earnings per share moved +1.5% while the price moved −11.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +7.2% a year; about +8.5% a year came from earnings growth and about −1.3 percentage points from the multiple (the market paying less); over 10 years the price moved +11.7% a year; about +13.4% a year came from earnings growth and about −1.7 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sree Rayalaseema Hi-Strength Hypo business getting better or worse? Sree Rayalaseema Hi-Strength Hypo Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 12.0%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Sree Rayalaseema Hi-Strength Hypo earn on its capital? Sree Rayalaseema Hi-Strength Hypo Ltd earned a ROCE of 14% in FY26. That is up from a low of 4% in FY17. Its return on capital used (ROIC) is 0.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 13.5% net margin and 0.60× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.5% net margin × 0.60× asset turnover × 1.15× leverage (assets divided by equity) ≈ 9.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 11.1% − 12.0% = −0.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Sree Rayalaseema Hi-Strength Hypo have too much debt? Sree Rayalaseema Hi-Strength Hypo Ltd has total debt of ₹12.0 Cr against shareholder equity of ₹984 Cr as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.05 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sree Rayalaseema Hi-Strength Hypo shareholding pattern? No group of Sree Rayalaseema Hi-Strength Hypo Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved +0.1 points over the same period, to 0.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +0.3 points over 8 quarters, to 62.2%; Foreign institutions: +0.1 points over 8 quarters, to 0.3%; Domestic institutions: +0.0 points over 8 quarters, to 0.1%. ## How far is Sree Rayalaseema Hi-Strength Hypo from balance-sheet trouble? For Sree Rayalaseema Hi-Strength Hypo Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sree Rayalaseema Hi-Strength Hypo rank in its industry? 52.0 out of 100, rank 6 of 9 in Chemicals - Inorganic, with 81% of the evidence available. Sree Rayalaseema Hi-Strength Hypo Ltd scores 52.0 out of 100 against the 9 companies it is compared with in Chemicals - Inorganic, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 15.5 + 12.9 + 12.9 + 10.7 = 52. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sree Rayalaseema Hi-Strength Hypo compared with? Sree Rayalaseema Hi-Strength Hypo ranks 6 of 9 Chemicals - Inorganic companies on the 4-Factor Sector Score, with 52.0 out of 100. 1. [Deepak Nitrite Ltd](https://www.sectoralpha.in/stocks/deepak-nitrite-ltd) DEEPAKNTR · quiet · Most evidence points up · 100% evidence 70.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.7/35 · Revenue 23.8% · Profit 100% · Operating margin change 9 points · 100% evidence Capital efficiency 12.4/25 · ROCE 11.4% · Operating margin 20% · 100% evidence Valuation 15.6/20 · P/E 19.4× · PEG 0.89 · 100% evidence Relative strength 9.3/20 · Lead over its industry -6.1% · Lead over NIFTY 500 -1.7% · 1 year -12.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 32.7 + 12.4 + 15.6 + 9.3 = 70 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Indo Borax & Chemicals Ltd](https://www.sectoralpha.in/stocks/indo-borax-chemicals-ltd) INDOBORAX · leader · Evidence leans up · 96% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.8/35 · Revenue 28.9% · Profit 47.4% · Operating margin change 5 points · 88% evidence Capital efficiency 18.6/25 · ROCE 15.4% · Operating margin 28% · 100% evidence Valuation 4.4/20 · P/E 25.5× · PEG 1.77 · 100% evidence Relative strength 11.8/20 · Lead over its industry 19.3% · Lead over NIFTY 500 22.2% · 1 year 44% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.8 + 18.6 + 4.4 + 11.8 = 59.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Ganesh Benzoplast Ltd](https://www.sectoralpha.in/stocks/ganesh-benzoplast-ltd) GANESHBE · losing its lead · Evidence leans up · 74% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 13.1% · Profit 87.2% · Operating margin change -7 points · 88% evidence Capital efficiency 11.2/25 · ROCE 14.5% · Operating margin 23% · 100% evidence Valuation 16.1/20 · P/E 9.7× · PEG 0.25 · 65% evidence Relative strength 8.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -3.7% · 1 year 1.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 21.1 + 11.2 + 16.1 + 8.7 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Tanfac Industries Ltd](https://www.sectoralpha.in/stocks/tanfac-industries-ltd) TANFACIND · leader · Evidence leans up · 76% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 13.2% · Profit -29.2% · Operating margin change -1 points · 83% evidence Capital efficiency 16.5/25 · ROCE 23.9% · Operating margin 15% · 95% evidence Valuation 8.5/20 · P/E 112× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 44.2% · Lead over NIFTY 500 48.6% · 1 year 82.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12 + 16.5 + 8.5 + 20 = 57 · What this means: Relative strength against the index is 48.6%, and revenue and profit growth are weak. 5. [J.G.Chemicals Ltd](https://www.sectoralpha.in/stocks/jgchemicals-ltd) JGCHEM · leader · Evidence leans up · 63% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.9/35 · Revenue 24% · Profit 16.4% · Operating margin change 2 points · 83% evidence Capital efficiency 15.5/25 · ROCE 17.7% · Operating margin 11% · 76% evidence Valuation 7.5/20 · P/E 29.3× · PEG n/a · 50% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 33.3% · 1 year 31.2% · 25% evidence · 12 of 12 weeks ahead Exact sum: 21.9 + 15.5 + 7.5 + 12 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Sree Rayalaseema Hi-Strength Hypo Ltd this page SRHHYPOLTD · breaking out · Evidence leans up · 81% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.5/35 · Revenue 7.6% · Profit 1.1% · Operating margin change -1 points · 88% evidence Capital efficiency 12.9/25 · ROCE 13.7% · Operating margin 14% · 100% evidence Valuation 12.9/20 · P/E 8.4× · PEG 1.29 · 100% evidence Relative strength 10.7/20 · Lead over its industry n/a · Lead over NIFTY 500 2.9% · 1 year -12.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 15.5 + 12.9 + 12.9 + 10.7 = 52 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [POCL Enterprises Ltd](https://www.sectoralpha.in/stocks/pocl-enterprises-ltd) POEL · Evidence leans down · 69% evidence 46.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.8/43.75 · Revenue 4.6% · Profit -2% · Operating margin change -3 points · 88% evidence Capital efficiency 19.8/31.25 · ROCE 26.6% · Operating margin 2.5% · 100% evidence Valuation 18.4/25 · P/E 12.2× · PEG 0.71 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 7.8 + 19.8 + 18.4 = 46 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Archean Chemical Industries Ltd](https://www.sectoralpha.in/stocks/archean-chemical-industries-ltd) ACI · quiet · Most evidence points down · 90% evidence 29.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 6.9/35 · Revenue 6% · Profit -43.3% · Operating margin change -3 points · 100% evidence Capital efficiency 9.6/25 · ROCE 7.4% · Operating margin 24% · 100% evidence Valuation 8.5/20 · P/E 54.7× · PEG n/a · 50% evidence Relative strength 4.8/20 · Lead over its industry -18.3% · Lead over NIFTY 500 -14% · 1 year -33.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 6.9 + 9.6 + 8.5 + 4.8 = 29.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fischer Medical Ventures Ltd](https://www.sectoralpha.in/stocks/fischer-medical-ventures-ltd) FISCHER · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 39.1% · Profit -80% · Operating margin change -269.5 points · 65% evidence Capital efficiency 1.8/25 · ROCE -1.6% · Operating margin -261.1% · 100% evidence Valuation 8.9/20 · P/E 58.4× · PEG n/a · 15% evidence Relative strength 1.7/20 · Lead over its industry -36.8% · Lead over NIFTY 500 -33.5% · 1 year -79% · 100% evidence · 2 of 12 weeks ahead Exact sum: 14.2 + 1.8 + 8.9 + 1.7 = 26.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Inorganic](https://www.sectoralpha.in/sectors/chemicals-inorganic), all 9 compared on one page. ## Which companies are close to Sree Rayalaseema Hi-Strength Hypo in size? Sree Rayalaseema Hi-Strength Hypo is the 7th largest of 9 Chemicals - Inorganic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Archean Chemical Industries, J.G.Chemicals, Fischer Medical Ventures and Indo Borax & Chemicals. Just below it: Ganesh Benzoplast and POCL Enterprises. ### Chemicals - Inorganic companies close in size

1. [Archean Chemical Industries Ltd](https://www.sectoralpha.in/stocks/archean-chemical-industries-ltd) ₹5,460 crore
2. [J.G.Chemicals Ltd](https://www.sectoralpha.in/stocks/jgchemicals-ltd) ₹2,204 crore
3. [Fischer Medical Ventures Ltd](https://www.sectoralpha.in/stocks/fischer-medical-ventures-ltd) ₹1,732 crore
4. [Indo Borax & Chemicals Ltd](https://www.sectoralpha.in/stocks/indo-borax-chemicals-ltd) ₹1,248 crore
5. Sree Rayalaseema Hi-Strength Hypo Ltd ₹833 crore
6. [Ganesh Benzoplast Ltd](https://www.sectoralpha.in/stocks/ganesh-benzoplast-ltd) ₹634 crore
7. [POCL Enterprises Ltd](https://www.sectoralpha.in/stocks/pocl-enterprises-ltd) ₹447 crore

[All 9 Chemicals - Inorganic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-inorganic#all-companies)

### Companies close in size in other industries

1. [Jindal Supreme (India) Ltd](https://www.sectoralpha.in/stocks/jindal-supreme-indialtd) ₹836 crore
2. [Hemant Surgical Industries Ltd](https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd) ₹834 crore · Medical Equipment
3. Sree Rayalaseema Hi-Strength Hypo Ltd ₹833 crore
4. [Madras Fertilizers Ltd](https://www.sectoralpha.in/stocks/madras-fertilizers-ltd) ₹832 crore · Fertilisers
5. [Sancode Technologies Ltd](https://www.sectoralpha.in/stocks/sancode-technologies-ltd) ₹832 crore · IT - Software

## What else do people ask about Sree Rayalaseema Hi-Strength Hypo? ### What is Sree Rayalaseema Hi-Strength Hypo's share price today? Sree Rayalaseema Hi-Strength Hypo Ltd's share price is ₹490.20, −11.2% over the past year. The whole company is worth ₹842 Cr on the market. In the last 52 weeks it traded between ₹407 to ₹597; today it is 44% of the way up from the low, 4.3% below its 200-day average (as of 3 November 2026). ### What were Sree Rayalaseema Hi-Strength Hypo's latest quarterly results? Sree Rayalaseema Hi-Strength Hypo Ltd reported revenue of ₹211 Cr and net profit of ₹25.0 Cr for the Jun 2026 quarter. Revenue rose 17.2% and profit rose 13.6% compared with a year earlier. Earnings per share were ₹14.28 (as of 3 November 2026). ### What is Sree Rayalaseema Hi-Strength Hypo's market cap? Sree Rayalaseema Hi-Strength Hypo Ltd's market capitalisation is ₹842 Cr at a share price of ₹490.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sree Rayalaseema Hi-Strength Hypo performing? Sree Rayalaseema Hi-Strength Hypo Ltd's share price has been rising for 5 weeks. In its latest quarter, revenue rose 17.2% and profit rose 13.6% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 11 weeks running (as of 3 November 2026). ### Will Sree Rayalaseema Hi-Strength Hypo's share price go up? This page does not forecast Sree Rayalaseema Hi-Strength Hypo Ltd's share price. What it shows instead: the share price is ₹490.20, and it has been rising for 5 weeks. Its P/E of 8.5× is higher than 37% of its own last 11 years (as of 3 November 2026). ### Who owns Sree Rayalaseema Hi-Strength Hypo? Promoters own 62.2% of Sree Rayalaseema Hi-Strength Hypo Ltd, foreign institutions 0.3%, domestic institutions 0.1% and the public 37.5% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Does Sree Rayalaseema Hi-Strength Hypo have too much debt? No, Sree Rayalaseema Hi-Strength Hypo Ltd has little debt: its debt is 0.01× its equity, and its operating profit is 44 times its interest bill. FY26 borrowings were ₹12.0 Cr against equity of ₹971 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sree Rayalaseema Hi-Strength Hypo in its business cycle? Sree Rayalaseema Hi-Strength Hypo Ltd's FY26 operating margin was 13.0%, against a 9-year range of 11.0% to 15.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 14.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sree Rayalaseema Hi-Strength Hypo story? Biggest thing to watch: the price has already been rising for 5 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sree Rayalaseema Hi-Strength Hypo a stock worth studying right now? What the numbers show: Sree Rayalaseema Hi-Strength Hypo Ltd's earnings have grown faster than its share price. Earnings per share grew +1.5% in a year while the price moved −11.2%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.